Fusion genes are a series of typical tumor biomarkers that can induce dysregulated gene expression and generate oncogenic proteins, both of which contribute to malignant transformation. Consequently, their detection is crucial for early cancer diagnosis, treatment selection, and prognostic evaluation. However, the existing fusion gene detection techniques remain constrained by time-consuming protocols, labor-intensive sample processing, and dependence on sophisticated instrumentation. To overcome these challenges, we present a rapid and portable photothermal biosensing platform utilizing DNA sandwich nanozymes (DSNs). The DSN integrates dual functionalities: a highly specific recognition probe for the BCR-ABL fusion gene, and a peroxidase-mimetic nanozyme that catalyzes the 3,3′,5,5′-tetramethylbenzidine (TMB)-H 2 O 2 ) redox reaction, producing both visible colorimetric signals and quantifiable photothermal effects. This strategy enables sensitive detection of the BCR-ABL fusion gene, providing a valuable tool for the early diagnosis and minimal residual disease monitoring of chronic myeloid leukemia.
He et al. (Wed,) studied this question.